Multi-day Doses in Prevention of Nausea and Emesis
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
To assess emetic responses to multi-day doses of Palonosetron and Aprepitant and low dose
dexamethasone +/- Prochlorperazine among patients with multiple myeloma and lymphoma
undergoing autologous HSCT utilizing the Multinational Association for Supportive Care in
Cancer (MASCC) Antiemesis Tool (MAT).
Phase:
Phase 2
Details
Lead Sponsor:
University of Kansas University of Kansas Medical Center